Antinuclear antibodies: A marker associated with steroid dependence in patients with ulcerative colitis

Background: The autoimmune phenomena and the autoantibody profile have acquired great importance in ulcerative colitis (UC). Few studies have explored antinuclear antibodies (ANAs) prevalence, but not its association with steroid dependence. We hypothesized that ANAs could be a factor associated to steroid dependence. Methods: Ninety‐seven consecutive patients with UC were included. ANA titers and staining patterns were determined by indirect immunofluorescence. Gender, age, follow‐up time, C‐reactive protein (CRP), disease extent, Mayo Score Activity Index, extraintestinal manifestations, and steroid dependence were analyzed in univariate and multivariate models. Results: Ninety‐seven patients were included and 49 (50.5%) were females; mean age was 41.7 ± 22.2 years. Positivity for ANAs was encountered in 52 (53.5%) patients, and none for anti‐dsDNA. The prevalence of ANAs was higher in steroid‐dependent than in nonsteroid‐dependent patients (77.8% versus 48.1%, P = 0.020; odds ratio [OR] = 3.8, 95% confidence interval [CI] 1.1–12.5), and in those with uveitis (100% versus 51.1%; P = 0.040) or pyoderma gangrenosum (100% versus 51.6%; P = 0.078). No association was observed with gender, age, CRP, disease extent, and Mayo Score Activity Index. The multiple regression analysis model showed an association between steroid dependence and ANAs (P = 0.033, OR = 3.9, 95% CI 1.4–14.9). Conclusions: ANAs are associated with steroid dependence in UC patients. Further studies are required to determine the role of ANAs as serological markers for prediction of steroid dependence in order to perform early therapeutic interventions with biological agents.

[1]  F. Gabilondo-Navarro,et al.  El Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán , 2010 .

[2]  A. Dall'aglio,et al.  Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis , 2007, Rheumatology International.

[3]  J. Gisbert,et al.  Papel de los marcadores biológicos en la enfermedad inflamatoria intestinal , 2007 .

[4]  I. Lavi,et al.  Antinuclear antibodies measured by enzyme immunoassay in patients with systemic lupus erythematosus: relation to disease activity , 2007, Rheumatology International.

[5]  W. Sandborn,et al.  Review article: biological activity markers in inflammatory bowel disease , 2006, Alimentary pharmacology & therapeutics.

[6]  J. Mate,et al.  [Role of biological markers in inflammatory bowel disease]. , 2007, Gastroenterologia y hepatologia.

[7]  L. Punzi,et al.  [Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatment with infliximab]. , 2011, Reumatismo.

[8]  D. Chang,et al.  [Comparative usefulness of erythrocyte sedimentation rate and C-reactive protein in assessing the severity of ulcerative colitis]. , 2006, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[9]  A. Darzi,et al.  Diagnostic Precision of Anti-Saccharomyces cerevisiae Antibodies and Perinuclear Antineutrophil Cytoplasmic Antibodies in Inflammatory Bowel Disease , 2006, The American Journal of Gastroenterology.

[10]  J. Yamamoto-Furusho,et al.  Perinuclear anti-neutrophil cytoplasmic antibodies (p-anca) in chronic ulcerative colitis: experience in a Mexican institution. , 2006, World journal of gastroenterology.

[11]  M. Majdan,et al.  [Association of ulcerative colitis and lupus nephropathy--report of two cases]. , 2006, Polskie Archiwum Medycyny Wewnetrznej.

[12]  F. Ajayi,et al.  Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial , 2005, The American Journal of Gastroenterology.

[13]  Dhiman Basu,et al.  Impact of Race and Ethnicity on Inflammatory Bowel Disease , 2005, The American Journal of Gastroenterology.

[14]  A. Zinsmeister,et al.  Correlation of C‐Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.

[15]  C. L. Colglazier,et al.  Featured CME Topic: Arthritis Laboratory Testing in the Rheumatic Diseases: A Practical Review , 2005 .

[16]  M. Rizzetto,et al.  The use of the anti-tumour necrosis factor monoclonal antibody--infliximab--to treat ulcerative colitis: implications and trends beyond the available data. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[17]  S. Endres,et al.  Antinuclear Autoantibodies in Patients with Inflammatory Bowel Disease (High Prevalence in First-Degree Relatives) , 1997, Digestive Diseases and Sciences.

[18]  E. Veys,et al.  Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. , 2003, Arthritis and rheumatism.

[19]  G. Porro,et al.  Inflammatory bowel disease: new insights into pathogenesis and treatment , 2002, Journal of internal medicine.

[20]  A. Zinsmeister,et al.  The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. , 2001, Gastroenterology.

[21]  J. Mccrea,et al.  A case of Sjögren's syndrome, sarcoidosis, previous ulcerative colitis and gastric autoantibodies , 1996, The British journal of dermatology.

[22]  E. Soppi,et al.  Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis. , 1995, Journal of clinical pathology.

[23]  J. Priddle,et al.  Serum and tissue autoantibodies to colonic epithelium in ulcerative colitis. , 1991, Gut.

[24]  S. Procaccia,et al.  Detection of rheumatoid factors of different isotypes and of circulating immune complexes in patients with inflammatory bowel disease. , 1990, Bollettino dell'Istituto sieroterapico milanese.

[25]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[26]  E. Schrumpf,et al.  An autoantibody profile in primary sclerosing cholangitis. , 1987, Journal of hepatology.

[27]  F. Bianchi,et al.  Antibodies to the cytoskeleton components and other autoantibodies in inflammatory bowel disease. , 1985, Digestion.